Next - DNA methyltransferase-tdcyd to#3 conduct studies $234,760 RAT (NX157-110-187-003)&$478,298 DOG (NX157-110-187-004) pre-clin TOX study of drug DEV for cancer patients HHSN261201600019I…
Ended Awarded Last action
- Contract number
- HHSN26100003
- Awardee
-
University Of Illinois UEI Y8CWNJRCNN91
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $761,043
Award facts
- Opportunity
-
- N02CM4700142 Solicitation number
- Preclinical toxicology of drugs developed for cancer patients Award Notice · Posted Apr 4, 2014
- Contract value 100% obligated
- $761,043.02 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541690 Other Scientific and Technical Consulting Services
- PSC
- R499 Support- Professional: Other
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 5 offers Multiple Award, Fair Opportunity
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Chicago, IL 60612, USA
- Legislative mandates
-
- Service Contract Act FAR subpart 22.10
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$38 | |
| Change Order | $48,023 | |
| Original award | $713,058 |
About this award
The National Cancer Institute issued a delivery order to the University of Illinois on September 1, 2016, with a ceiling value of $712,043.02, under the Toxicology of Drugs Developed for Cancer Patients IDIQ to conduct preclinical toxicology studies of a DNA methyltransferase inhibitor (TDCYD) in support of cancer drug development.
The order encompasses two study components: a rat study valued at $234,760 and a dog study valued at $478,298. Place of performance is Chicago, IL. Work is to be completed by August 31, 2017. The order is priced on a cost-plus-fixed-fee basis.
Description
Next - DNA methyltransferase-tdcyd to#3 conduct studies $234,760 RAT (NX157-110-187-003)&$478,298 DOG (NX157-110-187-004) pre-clin TOX study of drug DEV for cancer patients HHSN261201600019I DTP-16-064 TPB
Quick answers
Who was awarded contract HHSN26100003?
HHSN26100003 was awarded to University Of Illinois by National Cancer Institute (National Institutes of Health) on September 1, 2016.
How much is contract HHSN26100003 worth?
The government has obligated $761,043 on HHSN26100003.
Is contract HHSN26100003 an order under another contract?
Yes. HHSN26100003 is a delivery order under HHSN261201600019I, an indefinite delivery contract, on Toxicology of Drugs Developed for Cancer Patients.
Was contract HHSN26100003 competed?
The extent of competition for HHSN26100003 was full and open competition. The government received 5 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award